SONIRE Therapeutics CEO Tohru Satoh to speak at MEDICA 2024

SONIRE Therapeutics Inc. (Headquarters: Tokyo, Japan; President and CEO, Founder: Tohru Satoh; hereinafter referred to as “SONIRE”), announces that Mr. Tohru Satoh will be speaking at the Future of Therapy session of Pitch Event at MEDICA 2024, the world’s largest medical equipment trade fair, to be held in Düsseldorf, Germany from 11th to 14th November 2024. The title of the presentation will be “Cancer treatment using ultrasound technology”.

Date and time:
November 13th (Wed) 12:45 – 12:55 (CET) (20:45 – 20:55 (JST))
Place: MEDICA INNOVATION FORUM (MIF) Hall 13 Booth E63

For information on the presentations, please refer to the following website.
https://www.medica-tradefair.com/en/Program/Programoverview?ems_event=mif-cancer-treatment-using-ultrasound-technology-432066

SONIRE will continue to promote our business in order to realize the wish we put in our company name at the time of our foundation: ” Sonics brings new future full of hope to as many cancer patients and their families as possible.”.

Download PDF file

SONIRE’s HIFU therapy system has been designated as a Breakthrough Device by FDA

SONIRE Therapeutics Inc. (Headquarters: Tokyo, Japan; President and CEO, Founder: Tohru Satoh; hereinafter referred to as “SONIRE”), announces that the next-generation HIFU (High-Intensity Focused Ultrasound) therapy system (development code: Suizenji) developed by SONIRE has been designated as a breakthrough device by the U.S. Food and Drug Administration (hereinafter referred to as “FDA”) for the treatment of pancreatic cancer.

The Breakthrough Device Program supports the development of medical devices that provide more effective treatment or diagnostic of life-threatening or irreversible human diseases.

Through this program, SONIRE will receive an opportunity to interact with FDA experts through different program options to efficiently address topics as SONIRE arises during premarket review phase. Therefore, it is expected that this program accelerates for patients to access the new treatment provided by Suizenji as soon as possible.

For more information about the Breakthrough Device Program, please refer to the FDA website.
https://www.fda.gov/medical-devices/how-study-and-market-your-device/breakthrough-devices-program

SONIRE will continue to promote our business in order to realize the wish we put in our company name at the time of our foundation: ” Sonics brings new future full of hope to many cancer patients and their families as possible.”.

Download PDF file

HIFU treatment for pancreatic cancer will be broadcast on NHK WOLRD

SONIRE Therapeutics Inc. (Headquarters: Shinjuku-ku, Tokyo; President and CEO, Co-Founder: Tohru Satoh; hereinafter referred to as “SONIRE”), announces that NHK WOLRD’s “Medical Frontiers” will focus on HIFU therapy for pancreatic cancer, and the next-generation HIFU (High-Intensity Focused Ultrasound) therapy device, which has been developed by SONIRE, will be introduced in the program.

The program outline is as follows.
Title : Destroying Pancreatic Cancer With Ultrasound
Program Title : NHK World “Medical Frontiers”
Broadcast date and time :
January 8 (Mon) 23:30（JST）
January 9 (Tue) 05:30（JST）  [Rebroadcast]
January 9 (Tue) 12:30（JST）  [Rebroadcast]
January 9 (Tue) 18:30（JST）  [Rebroadcast]
January 27 (Sat) 04:30（JST） [NHK BS1]
Live streaming broadcast :
You can watch the live streaming from the official website.
https://www.nhk.or.jp/nhkworld/en/live/

On-demand Broadcasting :
After the rebroadcast ends, the program can be viewed for one year via on-demand broadcasting.
https://www.nhk.or.jp/nhkworld/en/tv/medicalfrontiers/

For details, please refer to the following URL.
https://www.nhk.or.jp/nhkworld/en/tv/medicalfrontiers/20240108/2050151/

SONIRE will continue to promote our business in order to realize the wish we put in our company name at the time of our foundation: ” Sonics（Ultrasound） Brings New Future to Cancer Patients and Families.”.

Download PDF file

Notice of Adoption being seleced for “Deep Tech Startup Support Program” by New Energy and Industrial Technology Development Organization (NEDO)

SONIRE Therapeutics Inc. (Headquarters: Shinjuku-ku, Tokyo; President and CEO, Co-
Founder: Tohru Satoh; hereinafter referred to as “SONIRE”), announces that our project
“Research and Development of Next-Generation Focused Ultrasound Therapy System for
Intractable Cancer” has been selected for the PCA (Product Commercialization Alliance)
phase of the Deep Tech Startup Support Program implemented by New Energy and Industrial
Technology Development Organization (NEDO).

The adoption of this program will further accelerate the development of our “next-generation
HIFU (High-Intensity Focused Ultrasound) therapy device”.

We will continue to promote our business in order to realize the wish we put in our company
name at the time of our foundation: ” Sonics（Ultrasound） Brings New Future to Cancer
Patients and their Families.”.

Download PDF file

Selected for the Olympus Asia Pacific Innovation Program

SONIRE Therapeutics Inc. (Headquarters: Shinjuku-ku, Tokyo; President and CEO: Tohru Satoh; hereinafter referred to as “SONIRE”), announces that it has been selected for the Olympus Asia Pacific Innovation Program (OAIP), which is organized by Olympus Corporation in cooperation with MedTech Innovator Asia Pacific.

The OAIP is open to startup companies with innovative technologies that contribute to minimally invasive treatments and lesion detection, diagnosis, and treatment in the medical device field and the grand prize winner will receive a mentorship program and reward from Olympus. The OAIP winners will also be selected as one of the MedTech Innovator Asia Pacific 2023 Cohort, which will be hosted by MedTech Innovator Asia Pacific, and will be provided with various support and opportunities to participate in the pitch. For more information, please see the news release regarding the MedTech Innovator Asia Pacific 2023 Cohort.

https://www.businesswire.com/news/home/20230606006132/en/MedTech-Innovator-Asia-Pacific-Names-24-Startups-to-Annual-Accelerator

We will continue to promote our business in order to realize the wish we put in our company name at the time of our foundation: ” Sonics（Ultrasound） Brings New Future to Cancer Patients and Families.”.

Download PDF file

SONIRE’s Clinical Trial Protocol for HIFU therapy in Pancreatic Cancer to be Presented at ISTU2023

SONIRE Therapeutics Inc. (Headquarters: Shinjuku-ku, Tokyo; President and CEO: Tohru Satoh; hereinafter referred to as “SONIRE”), announces that a clinical trial protocol for a HIFU therapy system currently underway in Japan for the treatment of patients with unresectable pancreatic cancer will be presented at the annual meeting of the International Society for Therapeutic Ultrasound held in Lyonn (France) from April 17 to 20, 2023.

Dr. Jun Sofuni, Associate Professor, Department of Gastroenterology, Division of Clinical Medicine, Tokyo Medical University and Chief, Department of Clinical Oncology, Tokyo Medical University Hospital, who is the investigator in charge of this clinical trial, will make two presentations at the following times.

April 18, 12:30 – 13:30 (local time) Poster Session

April 19, 13:30 – 13:48 (local time) Liver and Pancreas Session

Conference website: https://istu.org/istu-2023-lyon/　

An article about our business and cancer treatment using HIFU (High-Intensity Focused Ultrasound) was recently published in the Nikkei Newspaper. The development of our HIFU therapy system has entered a new stage and is attracting a great deal of attention both domestically and internationally.

We will continue to promote our business in order to realize the wish we put in our company name at the time of our foundation: ” Sonics（Ultrasound） Brings New Future to Cancer Patients and Families.”.

Download PDF file